Jason Bednar

Q: What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of 90.79794079139842.

Q: What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of 19.323871190511035.

Piper Sandler | Healthcare

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1319 out of 4508 analysts, they have issued 31 stock ratings with a success rate of 90.80% and an average return of 19.32%.

Jason Bednar has a well-established track record, with 31 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 90.80% and an average return of 19.32%, underscoring their expertise and ability to identify winning opportunities for investors.

#1319

Out of 4508

Total Ratings

+90.80%

Success Rate

+19.32%

Average Return

Recent Ratings Analysis

SHC

Buy

Jan 09, 2026

Target

$24.00

Current

$19.20

Performance

0.00%

Jason Bednar rated SHC as Overweight on Jan 09, 2026, setting a price target of 24. Shares have remained stable near 19.2, leaving the 24 target still in play.

COO

Buy

Dec 05, 2025

Target

$94.00

Current

$83.45

Performance

2.52%

On Dec 05, 2025, COO was given a Overweight rating by Jason Bednar, with a target price of 94. The stock traded sideways with a 2.52% move, keeping the bullish thesis unresolved.

SOLV

Buy

Nov 07, 2025

Target

$98.00

Current

$86.14

Performance

20.44%

SOLV received a Overweight rating from Jason Bednar on Nov 07, 2025, aiming for 98. Momentum has favored the Buy call, with shares climbing from 86.14 to 86.14, rewarding those who trusted the recommendation.

ICUI

Buy

Nov 07, 2025

Target

$172.00

Current

$152.99

Performance

9.15%

On Nov 07, 2025, Jason Bednar published a Overweight outlook on ICUI, with a target of 172. Shares gained 9.15%, underscoring the accuracy of the bullish outlook toward 172.

BDX

Hold

Nov 07, 2025

Target

$190.00

Current

$202.75

Performance

14.01%

Jason Bednar on Nov 07, 2025 assigned BDX a Neutral rating, with a price target of 190. Shares outperformed expectations, climbing 14.01% despite the neutral view.

MMSI

Buy

Oct 31, 2025

Target

$109.00

Current

$86.38

Performance

-1.33%

On Oct 31, 2025, Jason Bednar reaffirmed MMSI with a Overweight rating, targeting 109. Market indecision has kept the 109 target in a holding pattern.

ALGN

Buy

Oct 30, 2025

Target

$200.00

Current

$172.79

Performance

24.82%

ALGN was rated Overweight by Jason Bednar on Oct 30, 2025, with a price objective of 200. A bullish response from the market helped close the gap of 27.21 to the target.

MASI

Buy

Aug 06, 2025

Target

$210.00

Current

$138.92

Performance

-3.96%

On Aug 06, 2025, Jason Bednar initiated coverage on MASI with a Overweight rating and target of 210. Neutral price movement of -3.96% leaves room for interpretation.

NVST

Hold

Aug 01, 2025

Target

$19.00

Current

$23.63

Performance

13.44%

Jason Bednar issued a Neutral recommendation for NVST on Aug 01, 2025, price target set at 19. A neutral call gave way to stronger-than-expected performance, closing in on 19.

LUNG

Hold

Jul 31, 2025

Target

$2.50

Current

$2.04

Performance

10.87%

On Jul 31, 2025, LUNG was evaluated by Jason Bednar, who gave a Neutral rating and target of 2.5. Investors who stayed in despite the Hold saw upside of 10.87%.

NVCR

Buy

Jun 27, 2025

Target

$34.00

Current

$14.35

Performance

-20.28%

Jason Bednar rated NVCR as Overweight on Jun 27, 2025, setting a price target of 34. The stock has underperformed, dropping 20.28% despite the bullish target of 34.

EDAP

Buy

Mar 28, 2025

Target

$4.50

Current

$3.68

Performance

73.58%

On Mar 28, 2025, EDAP was given a Overweight rating by Jason Bednar, with a target price of 4.5. The stock rallied 73.58% after the rating, narrowing the gap to the target of 4.5 and validating the bullish stance.

KRMD

Hold

Feb 14, 2025

Target

$4.50

Current

$5.65

Performance

29.29%

KRMD received a Neutral rating from Jason Bednar on Feb 14, 2025, aiming for 4.5. Investors saw gains of 29.29% that the cautious stance didn’t fully capture.

STE

Buy

Feb 03, 2025

Target

$265.00

Current

$256.82

Performance

17.62%

On Feb 03, 2025, Jason Bednar published a Overweight outlook on STE, with a target of 265. Shares gained 17.62%, underscoring the accuracy of the bullish outlook toward 265.

PDCO

Hold

Dec 06, 2024

Target

$24.00

Current

$31.33

Performance

36.69%

Jason Bednar on Dec 06, 2024 assigned PDCO a Neutral rating, with a price target of 24. Shares outperformed expectations, climbing 36.69% despite the neutral view.

DRTS

Buy

Aug 15, 2024

Target

$7.00

Current

$6.93

Performance

208.00%

On Aug 15, 2024, Jason Bednar reaffirmed DRTS with a Overweight rating, targeting 7. The recommendation was supported by strong follow-through as the stock rose from 6.93 to 6.93.

XAIR

Buy

Jun 25, 2024

Target

$3.50

Current

$0.88

Performance

-93.19%

XAIR was rated Overweight by Jason Bednar on Jun 25, 2024, with a price objective of 3.5. This case shows how bullish projections can fail, with the stock now below 0.8839.

HSIC

Buy

Jun 21, 2024

Target

$86.00

Current

$77.64

Performance

15.43%

On Jun 21, 2024, Jason Bednar initiated coverage on HSIC with a Overweight rating and target of 86. The stock’s climb of 15.43% since the call highlights the foresight in the rating.

XRAY

Hold

May 03, 2024

Target

$32.00

Current

$12.78

Performance

-54.83%

Jason Bednar issued a Neutral recommendation for XRAY on May 03, 2024, price target set at 32. Market action validated the conservative Hold outlook with shares at 12.78.

Frequency Asked Questions

Who is Jason Bednar?

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of +90.80%.

How many ratings has Jason Bednar issued?

Jason Bednar has issued 31 stock ratings so far.

What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of +19.32%.

What is Jason Bednar's ranking?

Jason Bednar is ranked #1319 out of 4508 analysts.

What types of ratings does Jason Bednar give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jason Bednar?

You can follow Jason Bednar by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jason Bednar?

Their latest rating was a Buy on SHC issued on 2026-01-09.